New hope for dialysis patients: drug targets dangerous phosphate levels
NCT ID NCT00506441
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called MCI-196 in 245 adults on dialysis who have high phosphate levels, a common problem in advanced kidney disease. After a 4-week washout and 12-week dose adjustment, patients were randomly assigned to continue MCI-196 or switch to a placebo for 4 weeks. The main goal was to see if the drug keeps phosphate levels lower than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Glendale, Arizona, United States
-
Study site
Tempe, Arizona, United States
-
Study site
Hot Springs, Arkansas, United States
-
Study site
Paragould, Arkansas, United States
-
Study site
Pine Bluff, Arkansas, United States
-
Study site
Fountain Valley, California, United States
-
Study site
La Mesa, California, United States
-
Study site
Long Beach, California, United States
-
Study site
Lynwood, California, United States
-
Study site
Orange, California, United States
-
Study site
San Diego, California, United States
-
Study site
Whittier, California, United States
-
Study site
Brandon, Florida, United States
-
Study site
Hudson, Florida, United States
-
Study site
Lauderdale Lakes, Florida, United States
-
Study site
Tampa, Florida, United States
-
Study site
Augusta, Georgia, United States
-
Study site
Decatur, Georgia, United States
-
Study site
Macon, Georgia, United States
-
Study site
Evanston, Illinois, United States
-
Study site
Evergreen Park, Illinois, United States
-
Study site
Fort Wayne, Indiana, United States
-
Study site
Shreveport, Louisiana, United States
-
Study site
Springfield, Massachusetts, United States
-
Study site
Eatontown, New Jersey, United States
-
Study site
Flushing, New York, United States
-
Study site
Springfield Gardens, New York, United States
-
Study site
Allentown, Pennsylvania, United States
-
Study site
Lewistown, Pennsylvania, United States
-
Study site
Philadelphia, Pennsylvania, United States
-
Study site
Columbia, South Carolina, United States
-
Study site
Orangeburg, South Carolina, United States
-
Study site
Sumter, South Carolina, United States
-
Study site
San Antonio, Texas, United States
-
Study site
Alexandria, Virginia, United States
-
Study site
Portsmouth, Virginia, United States
-
Study site
Richmond, Virginia, United States
-
Study site
West Allis, Wisconsin, United States
-
Study site
San Juan, Puerto Rico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that boosts red blood cells help anemia in kidney disease?
- Predicting kidney trouble in older adults: a data-driven approach to clearer lab results
- Could delaying kidney implant during heart transplant reduce complications?
- Can a new tablet formulation improve how a kidney disease drug is absorbed?
- New drug aims to reduce kidney damage in chronic disease
- Contrast dye Double-Dose: new study tracks kidney fallout in ICU patients